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Wegener’s Granulomatosis:  
A comprehensive review
Maria Koukoulaki
A B S R A C T
Wegener’s Granulomatosis (WG) is a systemic multi-organ disease that is specifically 
characterised by inflammation of small and medium – sized vessels that could lead 
to tissue damage. Most commonly affected systems are the upper respiratory tract, 
the pulmonary, renal and ocular systems. Even though no diagnostic criteria have 
been established, the Chapel Hill Consensus definitions and the American College 
of Rheumatology classification criteria are widely used in clinical practice to identify 
WG. Definite diagnosis is confirmed by biopsy of the affected organ. This article 
reviews the epidemiology, pathophysiology, clinical manifestations, laboratory mark-
ers, diagnosis and disease assessment and, finally, the conventional and therapeutic 
options in WG.
I N T R O D U C T I O N
Systemic vasculitis comprises a group of multi-organ chronic diseases defined 
histologically as inflammation of the blood vessels that eventually results in organ 
damage [1]. Primary vasculitis is not related to any known underlying disorder while 
secondary vasculitis occurs as a manifestation of a co-existing disorder. The spectrum 
of organ involvement along with severity is quite diverse, complicating both the diag-
nosis and especially the treatment. The first case of systemic vasculitis was reported 
in 1866 by Kussmaul and Maier who described a disorder of nodular inflammation 
along the muscular arteries that they called “periarteritis nodosa” (later renamed 
polyarteritis nodosa) [2]. The first cases of Wegener’s Granulomatosis were described 
in the 1930s.
D e f I N I T I O N  A N D  C l A S S I f I C A T I O N  C R I T e R I A
Several classification schemes have been proposed for primary vasculitis. These 
are based on either the size of the vessels predominantly involved or the classifica-
tion criteria by the American College of Rheumatology (ACR) or the Chapel Hill 
Consensus Conference (CHCC) on nomenclature. 
Three categories are recognised for the classification of vasculitis according to 
size of vessel involved; large, medium and small vessel vasculitis [2,3]. In 1990, the 
ACR developed classification criteria for seven forms of vasculitis (polyarteritis 
nodosa [PAN], Churg-Strauss syndrome [CSS], Wegener’s Granulomatosis [WG], 
hypersensitivity vasculitis, Henöch Schölein Purpura [HSP], giant cell [temporal] 
arteritis, and Takayasu’s arteritis) [4] aiming to identify patients with a particular type 
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of vasculitis (sensitivity) and to exclude those who do not have 
vasculitis but suffer from other disorders (specificity). These 
criteria would establish uniform standards for the inclusion 
of patients in clinical, research or epidemiological trials. The 
determination of the classification criteria was based on the 
analysis of clinical data collected from 807 patients diagnosed 
with one of the seven forms of vasculitis over a five-year time 
period. Different combinations of clinical features of each 
form of vasculitis were evaluated before selecting the most 
discriminating variables to be considered as classification 
criteria [5]. It was clearly suggested that the ACR classification 
criteria were not diagnostic criteria, which was later confirmed 
at an audit using the ACR classification criteria as diagnostic 
criteria [6]. It was reported that applying ACR criteria for 
diagnosis of vasculitis led to identification of patients with 
vasculitis in 75% of the examined cases, but also another 21% 
of the patients met the ACR criteria without having vasculitis. 
Therefore, ACR criteria should not be used for the diagnosis 
of vasculitis. 
In 1994, the CHCC on the Nomenclature of Systemic Vas-
culitides proposed names and definitions for the most common 
forms of vasculitis based on the consensus of a committee of 
clinicians [7]. Except for the seven vasculitic types included in 
the ACR criteria, three more types of vasculitis were added: 
microscopic polyangiitis (MPA), Kawasaki disease [KD] and 
essential cryoglobulinaemic vasculitis.
Even though no diagnostic criteria have been developed 
for the diagnosis of vasculitides, the definitions of the CHCC 
along with the classification criteria of the ACR are widely 
used in clinical and research studies. It should be noted that 
CHCC definitions are based exclusively on pathological biopsy 
features while the ACR criteria take into account both clinical 
presentation and biopsy findings.
More specifically, according to the Chapel Hill Con-
sensus Conference on nomenclature (CHCC) definitions, 
WG is defined as vasculitis characterised by granulomatous 
inflammation of the respiratory tract and necrotising vascu-
litis affecting small to medium-sized vessels (e.g. capillaries, 
venules, arterioles and arteries) while a common finding is 
necrotising glomerulonephritis [7]. Classification criteria 
were developed by the American College of Rheumatology 
(ACR) by comparing 85 cases of WG with 722 control cases 
that were diagnosed with other types of vasculitis [8]. Criteria 
for the classification of WG are: 1) nasal or oral inflammation, 
defined as the development of painful or painless ulcers or 
purulent or bloody nasal discharge, 2) abnormal chest radio-
graph defined as a chest radiograph showing the presence 
of nodules, fixed infiltrates or cavities, 3) urinary sediment 
defined as microhaematuria (more than five red blood cells 
per high power field) or red cell casts in urine sediment, and 
4) granulomatous inflammation on biopsy, defined as histo-
logical changes showing granulomatous inflammation within 
the wall of an artery or in the perivascular or extravascular 
area (artery or arteriole) (Table 1). For the purposes of clas-
sification a patient shall be said to have WG if at least two 
of these four criteria are present. The presence of any two 
or more criteria is associated with a sensitivity of 88.2% and 
specificity of 92%. 
e p I D e m I O l O g y
The incidence and prevalence of systemic vasculitis are 
not well documented worldwide. Several reports suggest that 
in Europe, the overall annual incidence of primary systemic 
vasculitis including WG, microscopic polyangiitis (MPA) and 
Churg-Strauss Syndrome (CSS) is approximately 10-20/mil-
lion and also that the incidence increases with age showing a 
peak at the age group 65–74 [9-11]. More specifically, in the 
UK, the incidence of WG is 10.2/million, MPA 5.8/million 
and CSS 4.2/million [12]. A joint study by the Departments of 
Rheumatology in Norwich (Great Britain) and Lugo (Spain) 
showed that even though the incidence of primary systemic 
vasculitis is the same in the two regions, there are differences 
between certain types of vasculitis [13]. WG was more com-
mon in Norwich with an incidence 10.6/million compared to 
4.9/million in Lugo while the incidence of MPA was greater 
in Lugo (11.6/million) than in Norwich (8.4/million). This 
TABle 1. Definition and classification criteria of Wegener’s Granulomatosis adopted by the Chapel Hill Consensus 
Conference and the American College of Rheumatology respectively.
CHCC definition of Wegener’s granulomatosis
Granulomatous inflammation involving the respiratory tract, and necrotizing vasculitis affecting small to medium-sized vessels 
(e.g. capillaries, venules or arterioles). Necrotizing glomerulonephritis is common.
ACR Criteria for the classification of Wegener’s granulomatosis
1) nasal or oral inflammation, defined as the development of painful or painless ulcers or purulent or bloody nasal discharge; 
2) abnormal chest radiograph defined as a chest radiograph showing the presence of nodules, fixed infiltrates or cavities;
3) urinary sediment defined as microhaematuria (more than five red blood cells per high power field) or red cell casts in urine sediment,
 and 
4) granulomatous inflammation on biopsy, defined as histological changes showing granulomatous inflammation within the wall of an
 artery or in the perivascular or extravascular area (artery or arteriole).
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geographical pattern of incidence of vasculitis may reflect the 
impact of climatological factors. 
Additionally, other environmental or infectious param-
eters have been associated with systemic vasculitis. Exposure 
to high levels of silica  or inhalation of fumes, particulates and 
pesticides have been identified as risk factors for the devel-
opment of anti-neutrophil cytoplasmic antibodies (ANCA) 
- associated systemic vasculitis (AASV) and WG [14,15]. 
Furthermore, nasal carriage of Staphylococcus aureus has 
been associated with a high relapse rate in WG patients sug-
gesting a potential role in the pathogenesis of WG [16,17]. 
Finally, clinical observations and individual case reports note 
the onset of vasculitis following vaccination for influenza, 
smallpox, diphtheria, tetanus or hepatitis B [18,19].
pA T H O p H y S I O l O g y
The aetiology and pathophysiology of vasculitis is not well 
understood. However, both immune complexes of immuno-
globulins and complement as well as autoantibodies have been 
reported as mediators of the pathogenesis of vasculitis. In 
the early 1980s, the identification of autoantibodies directed 
against enzymes of the neutrophil cytoplasm provided a 
potential explanation of the mechanism that underlies the 
autoimmune response in vasculitis [20,21]. They were named 
anti-neutrophil cytoplasmic antibodies (ANCA) and up to 
date several types of ANCA have been described on the basis 
of their target. Two types of ANCA are the most important 
clinically and both have been correlated with systemic vas-
culitis. ANCA against proteinase 3 (PR3), a 29 kD serine 
protease found in neutrophils and monocytes, produce a 
diffuse granular cytoplasmic immunofluorescent staining (C-
ANCA) and they are associated predominantly with Wegener’s 
Granulomatosis. ANCA that target myeloperoxidase (MPO), 
a 140 kD enzyme of neutrophils, generate a perinuclear immu-
nofluorescent staining (P-ANCA) and they are linked mainly 
to MPA and renal limited vasculitis [22,23].
The mechanisms that lead to the breakdown of tolerance 
and the formation of ANCA remain uncertain. It is assumed 
that a genetic predisposition is essential but environmental 
factors are also important for disease onset. Clinical evidence 
suggests an association between bacterial (Staph. aureus) 
infection and vasculitis [16,17]. Potential pathways in the 
pathogenesis of ANCA that also apply to the pathogenesis of 
autoimmunity involve two mechanisms, molecular mimicry 
or infection-induced activation. Antigenic mimicry of host 
antigens (autoantigens) by microbial molecules may lead 
to activation of naοve T-cells resulting in autoreactivity. In 
addition, microbial infection can lead to tissue damage and 
release of host antigens and further activation of innate im-
munity and antigen-presenting-cells (APC). Up-regulation of 
host-antigens and major histocompatibility complex (MHC) 
by APC along with secretion of cytokines promote T-cells 
activation and recruitment of autoreactive lymphocytes. 
These mechanisms could trigger autoimmune reactions only 
in cases that innate regulatory mechanisms fail to recognise 
self antigens [24,25]. 
In vitro studies have revealed that ANCA can activate 
healthy neutrophils to produce oxygen radicals and release 
cytotoxic enzymes [26]. Pro-inflammatory cytokines such 
as tumour necrosis factor-alpha (TNFα) interleukin (IL)-1 
beta and IL-8 have been reported to induce degranulation of 
neutrophils [27-29]. Degranulation of neutrophils leads to the 
expression of the target antigens (PR3 and MPO) on the cell 
surface membrane which subsequently interacts with circulat-
ing ANCA [30,31]. Binding of ANCA to their target antigens 
results  in activation of neutrophils, apoptosis and the release 
of lytic enzymes. This interaction between PR3 and ANCA 
also seems to prevent the binding of PR3 to its natural inhibitor 
α1-antitrypsin [32]. Further on in the molecular pathway both 
F(ab)2 and Fc fragment are involved in this interaction, each 
activating a different pattern of gene expression [33,34]. 
In addition, ANCA can activate monocytes in vitro in a 
similar manner to neutrophils, via the production of oxygen 
radicals [35]. Furthermore, interaction of ANCA with its 
target antigen on endothelial cells leads to the expression of 
adhesion molecules and further adhesion of neutrophils and 
monocytes to endothelial cells which consecutively induces 
vascular endothelium injury [36-38].
In vivo studies will be required to definitely identify the 
immunological mechanisms underlying vasculitis but so far 
no experimental animal model of spontaneous vasculitis has 
been developed. MPO-knockout mice immunised with murine 
MPO develop antibodies against MPO, and transfer of anti-
MPO splenocytes to immunodeficient Rag2-/- mice results in 
small vessel vasculitis and necrotising crescentic glomerulo-
nephritis suggesting a causative role of MPO-ANCA in the 
pathogenesis of vasculitis [39].
In conclusion, ANCA seems to play a pivotal role in the 
pathogenesis of systemic vasculitis but the mechanisms that 
trigger disease onset have yet to be determined.
C l I N I C A l  m A N I f e S T A T I O N S
Symptoms of WG can be non-specific leading to a delay 
in the definite diagnosis of the disease. Organ involvement 
usually includes the upper respiratory tract, ears, eyes, lungs 
and kidneys. Systemic symptoms of fatigue, weakness, arthritis 
and skin manifestations are common while nervous system, 
cardiovascular or gastrointestinal involvement is less frequent 
[1,40,41].
The majority of patients with WG have upper respiratory 
tract symptoms that include nasal blockade with or without 
bloody nasal discharge, rhinitis, epistaxis, tenderness or pain 
over the paranasal sinuses. Inflammation of the nasal septum 
with septic sinusitis may lead to perforation and collapse of the 
nasal bridge resulting in saddle-nose deformity. Histologically, 
WG involves necrosis of medium size vessels with infiltration 
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by neutrophils and multinucleated giant cells specifically in 
the upper airway. Typically ear involvement includes either 
conductive or sensorineural hearing loss if the middle or in-
ner ear is affected respectively. Subglottic stenosis presents 
with hoarseness, difficulty in breathing, cough or inspiratory 
stridor, and can be a life-threatening complication. 
The pulmonary system is the second most commonly 
affected system following ENT (ear, nose, throat) in WG. 
Symptoms like cough, dyspnoea or haemoptysis are not 
diagnostic, but lung imaging with radiology or computed to-
mography usually reveals nodules, cavities, infiltrates, and in 
more severe cases alveolar haemorrhage. Respiratory failure 
requiring artificial ventilation can be fatal. On lung biopsy, 
a classic necrotizing granulomatous vasculitis is usually seen 
that is characterised by pulmonary angiitis with inflammation 
and necrosis of blood vessels with associated granuloma for-
mation. The granuloma consists of infiltrates of lymphocytes, 
plasma cells, epithelioid cells, or histiocytes with or without the 
presence of multinucleated giant cells and sometimes tissue 
necrosis. A small vessel capillaritis and intralveolar haemor-
rhage may also be found.  
Renal involvement presents with active urine sediment 
(haematuria) and a rise in serum creatinine. Kidney biopsy 
shows ischemic injury predominantly in the glomeruli and 
crescentic glomerulonephritis. Because of the absence of 
deposits of immunoglobulin or complement, renal vasculitis 
is called “pauci-immune” glomerulonephritis. 
Ocular features of WG commonly include conjunctivitis, 
episcleritis or orbital mass and proptosis due to retrobulbar 
inflammatory deposits. Scleritis, keratitis, uveitis may also be 
manifestations attributable to WG. 
Patients with WG quite frequently suffer from non-spe-
cific systemic symptoms like fatigue, musculoskeletal pains, 
arthralgia or fever. Cutaneous manifestations include palpable 
purpura and occasionally ulcers or nodules. Sensory peripher-
al neuropathy and motor mononeuritis are features of nervous 
involvement. Finally, WG may also affect the cardiovascular 
system causing aortic valve regurgitation.
l A B O R A T O R y  m A R K e R S 
ANCA are the only characteristic biomarker used in clini-
cal practice for both confirming the diagnosis and monitoring 
of systemic vasculitis. ANCA are not diagnostic for systemic 
vasculitis, nor does their absence exclude the possibility of 
vasculitis. As mentioned previously, two types of ANCA 
(C-ANCA and P-ANCA) have been associated with primary 
systemic vasculitis. This led to the definition of ANCA-Associ-
ated Systemic Vasculitis (AASV) which includes WG, MPA 
and CSS. The pattern of ANCA is determined by indirect 
immunofluorescent staining producing either a cytoplasmic 
staining C-ANCA or a perinuclear staining P-ANCA. En-
zyme-linked immunosorbent assays (ELISA) are used for 
detecting PR3-ANCA and MPO-ANCA and quantifying 
their titers. C-ANCA has been associated with WG and P-
ANCA with MPA. However, 10% of the WG patients may 
present positivity for P-ANCA. Even though the presence of 
ANCA can be useful to confirm diagnosis, their titer does not 
predict or correlate with disease activity. However, persistent 
positive ANCA after therapy for active disease or conversion 
to positive of previously tested negative ANCA is associated 
with an increased risk of disease relapse [42,43]. It has also 
been reported that monitoring of ANCA can be helpful in 
predicting relapse, suggesting pre-emptive modification of 
immune suppression in cases with four-fold increase of ANCA 
to prevent such relapse [44]. 
Acute–phase parameters or inflammatory markers like 
erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP) are usually elevated in cases with active disease but they 
are non-specific biomarkers and are certainly not diagnostic. 
They may be taken into consideration in assessing disease 
remission or monitoring disease flares but their value is quite 
questionable. 
D I A g N O S I S  –  D I f f e R e N T I A l  D I A g N O S I S
Diagnosis of the systemic vasculitides can be difficult 
since they are multi-organ diseases and also due to the fact 
that there is no consensus on diagnostic criteria. Because of 
the presentation of non-specific general symptoms at disease 
onset, vasculitis may not be diagnosed immediately, leading 
to subclinical progression of organ injury and damage. 
A definite diagnosis of WG is usually based on histological 
evidence of necrotizing granulomatous inflammation of the 
organs involved along with clinical features of upper and lower 
respiratory tract disease and frequently renal manifestations 
of glomerulonephritis. 
Differential diagnosis of WG can be challenging. Because 
of its multi-organ character, it has to be differentiated from 
other diseases with multi-organ involvement and inflamma-
tion. Firstly, it has to be discriminated from other forms of vas-
culitis like MPA, CSS, anti-glomerular basement membrane 
disease, and drug-induced AASV. Then, other autoimmune 
disorders like systemic lupus erythematosus (SLE) and sec-
ondary forms of vasculitis like rheumatoid vasculitis have to 
be excluded. Further, infections that can cause granulomata 
such as mycobacterium tuberculosis, mycobacterium avium 
or fungi have to be taken into consideration at the time of 
diagnosis. Finally, lymphomas and lung tumours are also in 
the differential diagnosis.
A S S e S S m e N T  O f  D I S e A S e  A C T I V I T y
As already mentioned, systemic vasculitis is a multi-or-
gan disorder that presents with differing severity and organ 
involvement. Serological and immunological parameters do 
not usually represent disease activity or indicate whether a 
therapeutic intervention is required. Moreover, vasculitis is 
a chronic disease characterised by periods of active disease, 
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remission or relapse that require different treatments. In 
other autoimmune diseases clinical indices are routinely 
used to assess disease activity, more specifically the Disease 
Activity Score is widely used in rheumatoid arthritis [45] 
and the British Isles Lupus Assessment (BILAG) is used in 
SLE [46]. Likewise, in systemic vasculitis, the Birmingham 
Vasculitis Activity Score (BVAS) was developed in the early 
90s to assess vasculitic manifestations [47]. The main objec-
tive of these scores is to transform qualitative data collected 
from clinical evaluation into quantitative measurements. The 
score is representative of disease activity and can be used to 
indicate or monitor the effectiveness of therapeutic interven-
tion, to compare between different time points in disease 
progression, as an unambiguous means of communication 
between physicians, and as a widely accepted clinical measure 
in clinical trials.
BVAS is an assessment tool that aims to standardise 
current disease activity and persisting clinical features that 
contribute to ongoing disease activity. Manifestations attrib-
uted to vasculitis are reported after excluding other possible 
causes. Sixty-six clinical features grouped into nine organ 
systems (general, cutaneous, mucous membranes/eyes, ENT, 
pulmonary, cardiovascular, abdominal, renal and nervous 
system) are included (Table 2). The presence of each one of 
the clinical features has a numerical value and each organ 
has a maximum score. A glossary of terms along with their 
values has been developed to accompany the BVAS form 
(Table 3). The European Vasculitis Study Group (EUVAS) 
has amended the BVAS so that it provides two scores; the 
BVAS 1 score reflects present or worse features and the BVAS 
2 score shows disease activity due to persistent manifestations 
of vasculitis within the last three months [48]. The main objec-
tive of BVAS 2 is to report grumbling and ongoing disease 
activity. Patients should be evaluated monthly when treated for 
newly diagnosed disease and three-monthly when disease is 
in remission. In clinical practice any increase of BVAS scores 
should be indicative of disease activity and treatment should 
be modified accordingly. 
Given that systemic vasculitis can lead to permanent dam-
age of the tissue and organs involved, another scoring system, 
the Vasculitis Damage Index (VDI), has been developed to 
document features attributable to systemic damage and not 
to current disease activity [49]. Damage is defined as any non-
healing scar that developed as a result of active vasculitis and 
which is unlikely to respond to further immune suppressive 
therapy. VDI is considered an assessment tool for measur-
ing damage due to either vasculitis activity or treatment and 
includes 64 features grouped into 11 organ systems (Table 4). 
VDI differs from BVAS because it reports any manifestation 
that has remained for more than three months. Each feature 
of VDI has the same numeric value and the VDI score is a 
cumulative assessment of organ dysfunction. The main utility 
of VDI is a predictor of mortality and since the items included 
are due to irreversible damage, the score would remain the 
same or increase but definitely not improve [50]. Any naοve 
patient would have zero VDI score and, thereafter, should be 
evaluated every six months or more to monitor permanent 
organ damage. 
Both BVAS and VDI are used in clinical trials and every 
day practice to record disease activity and chronic systemic 
damage in order to evaluate the progress of disease, efficacy 
of drug therapy and predict long-term survival. It should be 
mentioned that although both BVAS and VDI can be applied 
to all forms of systemic vasculitis, recently the International 
Network for Study of Systemic Vasculitis (INSSYS) has re-
viewed BVAS and developed a version to be specifically used 
in WG [51]. 
T H e R A p y  O f  W e g e N e R ’ S  g R A N U l O m A T O S I S
Systemic vasculitides are usually characterised by a relaps-
ing-remitting course of disease progression. Even though the 
general principles of treatment apply to all types of vasculitis, 
the therapeutic options for WG will be thoroughly described. 
At presentation, induction therapy is administered to induce 
remission with potent regimens including cyclophosphamide 
(CYC) or methotrexate (MTX) complemented with cortico-
steroids. Maintaining remission can be challenging but crucial 
to avoid relapse and after the completion of induction therapy, 
alternative immune suppressive agents, such as azathioprine 
(AZA) or mycophenolate mofetil (MMF), are administered to 
maintain remission. In cases of relapse or grumbling disease, 
therapeutic intervention is required either with conventional 
or novel treatments.
Corticosteroids were the first immune modulator to be 
used in the treatment of vasculitis and they still remain a 
major component of most immune suppressive regimens used 
to treat WG today [52]. While they rapidly control disease 
activity, they do not induce remission when administered as 
monotherapy and, therefore, they are administered in combi-
nation with other immune suppressive drugs. Steroids such as 
prednisolone are given at a dose of around 1 mg/kg in mostly 
newly diagnosed cases. This dose is slowly tapered to avoid the 
severe adverse events associated with their continuous admin-
istration. Intravenous methylprednisolone may be beneficial, 
especially, in active vasculitic glomerulonephritis [53]. 
First line therapy for induction of remission in active WG is 
the use of CYC. Daily oral administration of 2 mg/kg/day CYC 
with prednisolone has proven efficacy to achieve complete 
remission in 75% of patients and significant improvement in 
91% [40]. CYC can cause significant cytotoxic events both in 
the short-term, including the suppression of bone marrow, neu-
tropenia and infection and in the long-term such as infertility, 
bladder malignancy and myelodysplastic disorders [54]. It has 
been suggested that intermittent intravenous bolus treatment 
with CYC may eliminate these adverse reactions especially if 
adjusted for age and renal impairment [55,56].
WEGENER’S GRANULOMATOSIS
143
TABle 2. Birmingham Vasculitis Activity Score (BVAS)
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TABle 3. Glossary and definition of terms as well as score for each item included in the Birmingham Vasculitis Activity 
Score (BVAS)
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TABle 4. Vasculitis Damage Index (VDI)
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MTX has been evaluated as an alternative treatment for 
active AASV (WG and MPA) in a prospective randomised 
trial against CYC. This showed that MTX induced remission 
in 90% of patients [57]. However, a slightly, albeit non-sig-
nificant, higher rate of relapse was also reported, perhaps 
indicating the need for longer periods of maintenance therapy. 
Formerly, reports by Langford et al. and Reinhold-Keller et 
al. reviewed the use of MXT as a remission maintaining agent 
[58,59]. Even though MTX was relatively well tolerated, the 
relapse rate with renal involvement warranted further study.
Maintaining remission in WG is an essential factor of 
patient survival. The safety and efficacy of AZA, a metabolite 
of 6-mercaptopurin inhibiting purine synthesis, as a remission 
maintenance therapy has been assessed by EUVAS [60]. It was 
shown that replacement of CYC after induction of remission 
with AZA did not have an impact on disease relapse and that 
AZA may be used to prevent long-term exposure to CYC.
MMF, the prodrug of mycophenolic acid, which non-com-
petitively reversibly inhibits inosine monophosphate dehydro-
genase and purine synthesis, has also been introduced in the 
therapy of WG either as a remission maintenance agent or as 
a treatment for disease relapse. Preliminary reports indicated 
that MMF had variable efficacy of (10 - 43%) in sustaining 
remission for more that twelve months [61,62]. In a recent 
retrospective study, it was demonstrated that MMF can induce 
remission in WG when administered for disease flare but it 
was observed that low MMF doses could be responsible for 
higher relapse rates [63]. 
Additional therapy with intravenous immunoglobulin 
(IVIg) can supplement induction immune suppressive regi-
mens in cases of relapsing or refractory WG. In a randomized 
trial comparing IVIg with placebo when administered with 
steroids and another immune suppressive agent, it was shown 
that IVIg can improve clinical response [64]. The impact of 
IVIg on clinical outcome appears to be temporary, but it can 
be used for critical cases where there is an urgent need to 
rapidly control disease activity.
Novel therapeutic options that target specific parts in the 
pathogenesis pathway of vasculitis have become available 
for clinical investigation. Alemtuzumab (CAMPATH-1H), 
a humanised monoclonal antibody against CD52, a surface 
antigen of T- and B-lymphocytes, leads to lymphocyte deple-
tion and has been used successfully in difficult refractory 
cases of WG, but its toxicity, namely infections and infusion 
reactions, has restrained its further use [65]. Tumour necrosis 
factor alpha (TNFα) is considered an important component 
in the pathophysiology of vasculitis and, as a result, treatment 
with anti-TNFα agents such as the monoclonal antibody inf-
liximab, and the soluble TNF receptor etanercept, has been 
examined. Infliximab has proven efficacy in 88% of refractory 
or relapsing cases of vasculitis [66]. However, it was shown 
that etanercept did not improve relapse rates when adminis-
tered as concomitant treatment with CYC and steroids [67]. 
Furthermore, the role of B-cells in WG has received special 
interest. B-cell depletion with rituximab, a chimeric monoclo-
nal antibody targeting CD20 that is expressed on B-cells, has 
been effective in inducing remission in refractory cases of WG 
[68,69]. Rituximab satisfactorily controlled disease activity, 
ANCA titers fell, the daily steroid dose was significantly de-
creased and the drug was very well-tolerated. It was noted that 
in the majority of cases remission was sustained as long as the 
B-cells were undetectable, suggesting that repeated courses 
of rituximab may be necessary to prevent disease flares. 
Initial studies of 15-deoxyspergualin (DSG) have shown its 
safety and efficacy in refractory WG [70]. A European clinical 
trial of DSG in WG has been recently completed indicating 
particular specificity of DSG to control manifestations of the 
upper and lower respiratory tract (personal communication 
Dr O Flossmann).
In addition to the medical treatments described, non-phar-
macological interventions like plasma exchange or dilatation 
of the trancheo-bronchial tree can be useful, especially in 
life-threatening cases. Plasma exchange removes pathogenic 
autoantibodies and other factors that may trigger disease 
activity and has proven beneficial in cases of severe glomeru-
lonephritis and alveolar haemorrhage [71], although there is 
still no specific indication for plasma exchange in WG and no 
definite protocol for its use. In addition, subglottic stenosis is a 
frequent clinical feature of WG patients and usually indicates 
permanent scarring and fibrosis that is unlikely to respond to 
drug therapy. Dilatation of stenotic areas and possibly in situ 
steroid injections, can secure the patency of airways [72]. 
S U m m A R y 
Wegener’s Granulomatosis (WG) as a systemic multi-
organ disease, targets small and medium-sized vessels that 
could lead to tissue damage. The upper respiratory tract, the 
pulmonary, renal and ocular systems are usually affected. In 
absence of diagnostic criteria, biopsy of the affected organ can 
only confirm diagnosis. Induction treatment usually consists of 
high doses of steroids along with cyclophosphamide. In cases 
without severe organ, especially renal or pulmonary, dysfunc-
tion on presentation, methotrexate could be administered 
as an alternative. Maintaining remission with azathioprine 
or mycophenolate mofetyl is essential in addition to regular 
monitoring with BVAS and laboratory parameters to prevent 
disease relapses and treat grumbling disease activity.
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